ERBB2 and breast carcinoma: Our study aimed to perform a systematic review to compare the relative diagnostic accuracy of HER2-enriched subtypes and the presence of PIK3CA mutations, namely, TILs, HRs, and Ki-67, in predicting the degree of pCR to neoadjuvant therapy with HER2-targeted drugs in patients with HER2-positive breast cancer.